Literature DB >> 26191133

Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.

Shu-Jie Pang1, Cheng-Cheng Li2, Yan Shen1, Yian-Zhu Liu3, Yi-Quan Shi4, Yi-Xin Liu1.   

Abstract

The diagnosis of uterine smooth muscle tumors including leiomyosarcomas (LMS), smooth muscle tumors of uncertain malignant potential (STUMP), bizarre (atypical) leiomyoma (BLM), mitotically active leiomyoma (MAL) and leiomyoma (LM) depends on a combination of microscopic features, such as mitoses, cytologic atypia, and coagulative tumor cell necrosis. However, a small number of these tumors still pose difficult diagnostic challenges. The assessment of accurate mitotic figures (MF) is one of the major parameters in the proper classification of uterine smooth muscle tumors. This assessment can be hampered by the presence of increased number of apoptotic bodies or pyknotic nuclei, which frequently mimic mitoses. Phospho-histone H3 (PHH3) is a recently described immunomarker specific for cells undergoing mitoses. In our study, we collected 132 cases of uterine smooth muscle tumors, including 26 LMSs, 16 STUMPs, 30 BLMs, 30 MALs and 30 LMs. We used mitosis specific marker PHH3 to count mitotic indexes (MI) of uterine smooth muscle tumors and compared with the mitotic indexes of hematoxylin and eosin (H&amp;E). There is a positive correlation with the number of mitotic figures in H&amp;E-stained sections and PHH3-stained sections (r=0.944, P<0.05). The ratio of PHH3-MI to H&amp;E-MI has no statistically significant difference in each group except for LMs (P>0.05). The counting value of PHH3 in LMSs have significantly higher than STUMPs, BLMs, MALs and LMs (P<0.001) and the counting value of PHH3 is 1.5±0.5 times of the number of mitotic indexes in H&amp;E. To conclude, our results show that counting PHH3 is a useful index in the diagnosis of uterine smooth muscle tumors and it can provide a more accurate index instead of the time-honored mitotic figure counts at a certain ratio.

Entities:  

Keywords:  PHH3; Uterine smooth muscle tumors; immunohistochemical; mitotic index

Mesh:

Substances:

Year:  2015        PMID: 26191133      PMCID: PMC4503005     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

1.  Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation.

Authors:  H Goto; Y Tomono; K Ajiro; H Kosako; M Fujita; M Sakurai; K Okawa; A Iwamatsu; T Okigaki; T Takahashi; M Inagaki
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project.

Authors:  P J van Diest; J P Baak; P Matze-Cok; E C Wisse-Brekelmans; C M van Galen; P H Kurver; S M Bellot; J Fijnheer; L H van Gorp; W S Kwee
Journal:  Hum Pathol       Date:  1992-06       Impact factor: 3.466

3.  Can you count on the mitotic index?

Authors:  T J O'Leary; M W Steffes
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

4.  Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation.

Authors:  M J Hendzel; Y Wei; M A Mancini; A Van Hooser; T Ranalli; B R Brinkley; D P Bazett-Jones; C D Allis
Journal:  Chromosoma       Date:  1997-11       Impact factor: 4.316

5.  Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity.

Authors:  Coya Tapia; Heinz Kutzner; Thomas Mentzel; Spasenija Savic; Daniel Baumhoer; Katharina Glatz
Journal:  Am J Surg Pathol       Date:  2006-01       Impact factor: 6.394

6.  Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.

Authors:  Howard Colman; Caterina Giannini; Li Huang; Javier Gonzalez; Kenneth Hess; Janet Bruner; Gregory Fuller; Lauren Langford; Christopher Pelloski; Joann Aaron; Peter Burger; Ken Aldape
Journal:  Am J Surg Pathol       Date:  2006-05       Impact factor: 6.394

7.  The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.

Authors:  Teresa Ribalta; Ian E McCutcheon; Kenneth D Aldape; Janet M Bruner; Gregory N Fuller
Journal:  Am J Surg Pathol       Date:  2004-11       Impact factor: 6.394

8.  Phosphohistone H3 labelling for histoprognostic grading of breast adenocarcinomas and computer-assisted determination of mitotic index.

Authors:  C Bossard; A Jarry; C Colombeix; K Bach-Ngohou; A Moreau; D Loussouarn; J-F Mosnier; C L Laboisse
Journal:  J Clin Pathol       Date:  2006-02-03       Impact factor: 3.411

9.  Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus.

Authors:  Y L Zhai; T Nikaido; T Toki; A Shiozawa; A Orii; S Fujii
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

10.  A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens.

Authors:  I S Scott; T M Heath; L S Morris; S M Rushbrook; K Bird; S L Vowler; M J Arends; N Coleman
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.